Compare Icl Group Ltd (ICL) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Stryker Corporation — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 16.4× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Stryker Corporation for 21 Days on average.
| ICL | SYK | |
|---|---|---|
Market Cap | $6.47B | $106.24B |
Volume | 1,387,140 | 2,982,001 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $388.35 |
52-Week Low | $4.80 | $269.75 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | $9.11B | $117.70B |
Dividend Yield | 4.11% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 1.57% today, with a bearish technical signal from moving averages but a neutral oscillator stance. Recent earnings beat estimates in Q1 and Q2 2026, though revenue and net income have trended lower from 2022 peaks. The company maintains a dividend, with a $0.06 payment scheduled for September 2026, and operates with stable cash flow from operations around $1.1 billion.
The outlook is mixed: valuation ratios like P/E of 20.83 and P/S of 0.84 suggest reasonable pricing, but analyst consensus is entirely Hold with a $6.08 target. Risks include industry headwinds from higher input costs and competitive pressures, while institutional buying, like Amundi's Q1 2026 purchase, offers support. Earnings growth and cost transformation are key to upside.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
